Fifty 1 Labs, Inc. and The Gates Foundation Lead Largest-Ever Sickle Cell Disease Study, Unlocking Pathways for Gene-Based and Repurposed Therapies

Landmark AI-driven analysis backed by The Gates Foundation sets stage for transformative treatments in one of the world's most underserved diseases

VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, Inc. (OTC: FITY), a leader in AI-powered drug repurposing and precision medicine, today announced the completion of the largest and most comprehensive study of Sickle Cell Disease (SCD) ever undertaken. Leveraging a decade's worth of real-world patient data, the study mapped disease progression and treatment outcomes at an unprecedented scale—marking a major milestone in the fight against this life-threatening genetic disorder.

Funded by The Gates Foundation and conducted in collaboration with scientists from the University of Pittsburgh School of Medicine and the Stellenbosch University Centre for Infectious Diseases in South Africa, the groundbreaking research delivers the most detailed understanding to date of SCD's clinical landscape.

"This is more than a scientific achievement—it's a turning point," said Paul Arora, CEO of Fifty1 AI Labs. "By combining AI-driven analytics with world-class partnerships, we are accelerating the path toward affordable, effective treatments for millions who have long been overlooked."

The study's findings have been submitted to one of the world's most respected hematology journals and will be presented this September at a specialist conference in Senegal, drawing leading global experts in blood disorders.

Beyond its academic and clinical impact, the study serves as a catalyst for next-generation gene-based therapies and the repurposing of existing medicines—two approaches that can dramatically shorten timelines and reduce costs in bringing new treatments to market. With an estimated 7.74 million people worldwide living with SCD—most in sub-Saharan Africa and among people of African descent—this work addresses one of the highest-burden, least-served health challenges globally.

Powered by advanced analytics technologies pioneered at Fifty1 AI Labs, the project demonstrates how AI can mine real-world clinical data at scale, uncovering insights that can transform treatment strategies across multiple disease areas.

About Fifty1 AI Labs, Inc.

Fifty1 AI Labs is revolutionizing drug development through AI-driven analytics, focusing on uncovering novel therapeutic applications for existing drugs and developing precision medicine solutions. The company's platform integrates large-scale clinical, genomic, and patient outcome data to accelerate treatment innovation across global health challenges.

Contact:
Investor Relations
Fifty 1 Labs, Inc.
ir@fifty1labs.com | (877) 505-5006
www.fifty1AIlabs.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding the potential impact, development, and timeline of gene-based therapies and repurposed treatments for Sickle Cell Disease, the anticipated presentation of study findings at a specialist conference, and the ability of Fifty1 AI Labs' platform to transform treatment strategies across multiple disease areas, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause the company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the success and timing of clinical trials, regulatory approvals, the efficacy and safety of potential treatments, and the company's ability to successfully develop and commercialize its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, please refer to Fifty1 AI Labs' filings with the OTC Markets. The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.